Marcus Borenäs
-
ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK
mutation.
Marcus Borenäs, Ganesh Umapathy, Wei-Yun Lai, Dan Emil Lind, Barbara Witek, Jikui Guan, Patricia Mendoza-García, Tafheem Masudi, Arne Claeys, Tzu-Po Chuang, Abeer El Wakil, Badrul Arefin, Susanne Fransson, Jan Koster, Mathias Johansson, Jennie Gaarder, Jimmy Van den Eynden, Bengt Hallberg, Ruth H. Palmer
The EMBO journal - 2021 -
Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUG alpha) in neuroblastoma patient samples with chromosome arm 2p
rearrangements
Niloufar Javanmardi, Susanne Fransson, Anna Djos, Ganesh Umapathy, Malin Östensson, J. Milosevic, Marcus Borenäs, Bengt Hallberg, P. Kogner, Tommy Martinsson, Ruth H. Palmer
Genes Chromosomes & Cancer - 2020 -
Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma
cells.
Diana Lizeth Cervantes-Madrid, Joanna Szydzik, Marcus Borenäs, Mats Bemark, Jean Cui, Ruth H. Palmer, Bengt Hallberg
Scientific reports - 2019